Regulatory strategy is one of the most complex and important aspects of advanced therapy development. As advanced therapies continue to evolve, developers face a regulatory landscape that is both highly demanding and constantly adapting to scientific innovation.

As advanced therapies continue to evolve, developers face a regulatory landscape that is both highly demanding and constantly adapting to scientific innovation. For many organisations — particularly small biotech companies, hospital-based initiatives and academic spin-outs — understanding how to navigate this environment becomes a critical part of development.

Regulatory strategy starts earlier than many developers expect

One of the recurring challenges in advanced therapy development is that regulatory considerations often arrive later than they should.

Many early-stage developers initially focus on scientific proof of concept, while regulatory planning tends to be incorporated only when preparing for clinical trials. However, in ATMPs, regulatory strategy has a direct impact on how products are classified, developed, manufactured and ultimately authorised.

Early regulatory guidance can help developers define the appropriate development pathway, identify applicable requirements, structure documentation correctly and avoid unnecessary delays later in development.

Small organisations face additional challenges

In Europe, a significant proportion of ATMP development is driven by:

• Startups
• Academic institutions
• Hospital-based groups
• Small biotech companies

These organisations often operate with limited financial resources, making it difficult to maintain dedicated in-house regulatory teams or external regulatory support.

At the same time, advanced therapies require highly specialised regulatory expertise due to the complexity of the products involved and the evolving nature of the applicable frameworks.

As a result, many organisations face the challenge of advancing innovative therapies while simultaneously building the regulatory knowledge needed to support development.

Advanced therapies require product-specific regulatory approaches

Although advanced therapies follow many of the same major regulatory procedures as conventional medicines, including clinical trial applications and marketing authorisation processes, the content and structure of the required documentation can differ substantially.

One of the first critical steps is determining the correct classification of the product:

• Gene therapy
• Cell therapy
• Tissue-engineered product
• Combined ATMP

This classification influences the applicable guidelines, the type of supporting studies required, manufacturing expectations and the overall regulatory strategy.

In some cases, classification is not straightforward. Products involving genetic modification, for example, may not necessarily be classified as gene therapies depending on the characteristics of the final administered product.

For this reason, early interaction with regulatory authorities can play an important role in clarifying development pathways.

Manufacturing complexity creates additional regulatory challenges

One of the distinctive characteristics of advanced therapies is the complexity of their manufacturing processes.

Unlike conventional medicines based on defined chemical substances, ATMPs often involve continuous biological manufacturing processes where distinguishing between active substance and finished product is not always straightforward.

This can create challenges when preparing regulatory dossiers structured according to traditional pharmaceutical frameworks.

In these situations, developers may need to explain how documentation has been organised and how manufacturing stages have been defined within the submission.

Regulatory agencies generally allow flexibility in dossier structure provided that the documentation clearly demonstrates product quality, safety and control.

Scientific advice has become increasingly important

As technologies become more innovative, developers increasingly rely on scientific advice procedures and regulatory interaction mechanisms offered by agencies such as the EMA and national authorities.

These interactions may include:

• Scientific advice meetings
• Innovation task forces
• PRIME-related support
• Classification procedures for ATMPs

For highly innovative products where existing regulations may not fully address emerging technologies, these interactions help developers and regulators align expectations early in development.

In many cases, regulatory frameworks evolve progressively alongside scientific innovation itself.

GMO requirements add another layer of complexity

For therapies involving genetically modified organisms (GMOs), developers may also need to obtain additional authorisations beyond standard medicinal product approvals.

These GMO-related procedures can differ between European countries, creating additional complexity for multinational development programmes and clinical trials.

Efforts are currently underway within the European regulatory framework to further harmonise these procedures across member states, particularly as part of broader pharmaceutical legislation updates.

Hospital exemption pathways remain an important mechanism

The discussion also highlights the role of hospital exemption pathways for certain advanced therapies.

Under these frameworks, some ATMPs may be authorised for non-routine use within a specific hospital, under the responsibility of a medical specialist and for individual patients.

These pathways differ from full industrial marketing authorisations and are regulated differently across European countries.

Examples such as ARI-0001 in Spain have demonstrated the importance of these frameworks in enabling access to innovative therapies developed within hospital environments.

Regulatory agencies are evolving alongside innovation

One of the clearest trends in advanced therapy regulation is the growing openness of regulatory agencies towards early dialogue and collaborative interaction with developers.

Over time, regulatory authorities have increasingly positioned themselves not only as evaluators, but also as partners helping guide the safe and effective development of innovative medicines.

As advanced therapies continue to evolve, regulators and developers often learn simultaneously through emerging technologies and novel therapeutic approaches.

This collaborative dynamic has become an important part of the ATMP ecosystem, particularly in areas where scientific innovation advances faster than existing regulatory frameworks.

Building regulatory thinking into development from the beginning

Advanced therapy development requires much more than scientific innovation alone.

Integrating regulatory strategy from the earliest stages helps developers:

• Better structure development programmes
• Anticipate future requirements
• Reduce avoidable delays
• Improve the overall pathway towards clinical application and patient access

In highly innovative and rapidly evolving fields such as ATMPs, early regulatory planning is increasingly becoming part of the scientific development process itself.